From 16 to 18 February 1984, workshops were held on the fo llowing subjects: Experimental Leprosy; Microbiology; Immunology; Experimental Chemo therapy; Epidemiology and Control; Teaching and Training; Social Aspects. As on the occasion of previous congresses, thereports were prepared by the chairmen and rapporteurs and distributed to all delegates.
Experimental leprosy
The workshop reviewed advances in the last 5 years in 4 major animal models of experimental leprosy: a, immunologically-intact mice; b, armadillos; c, athymic, nude mice and rats; and d, primates.
Immunologically-intact mice continue to be the experimental leprosy model of choice for determining drug sensitivity of clinical isolates of My cobacterium leprae, for routine determination of viability of M. leprae, for determining the bacteriostatic or bactericidal act jon of anti leprosy drugs and other uses. A newer model was presented consisting of an immune tolerant animal fo llowing the intravenous injection of 107 M. leprae in na · ive mice. In mice rendered tolerant by intravenous injection of M. leprae, intradermal challenge does not result in DTH . Various potential antileprosy vaccines have been used as a means of overcoming this tolerance. With the possible exception of BCG, none have been successful.
Armadillos continue to be utilized primarily for the production of M. leprae. Armadillos fr om the USA consistently are capable of yielding large numbers of M. leprae (more than 109 bacilli per gram of tissues fr om liver, spleen and lymph nodes) within approximately 2 years of inoculation with viable bacilli. Wild armadillos caught in the USA sometimes have a variety of other infections including: a, natural infection with M. leprae; b, Sp orotrichium shenkii (up to 63%); c, coryneform organisms; d, cultivable mycobacteria; e, Trypanosome cruzii; f, Salmonella typhimurium, Coccidiodosis, etc. Natural infection with My cobacterium leprae seems to be fo und in Texas and Louisiana but not in Florida, USA. Successful breeding of nine-banded armadillos (Dasyp us novem cinctus) in captivity has occurred in Brazil. Experimental transmission has also been successful with D. hybridus in Argentina. This species is of considerable interest since it breeds easily in captivity. 0305-7518/84/055191 + 15 $0 1 .00 © British Leprosy Relief Association A number of laboratories around the world are now working with nude mice as a model of lepromatous leprosy. Yields of bacilli as high as 1011 per mouse have been reported 18 months after inoculation with high doses of My cobacterium leprae. In Nepal, excellent survival of nude mice has been reported in a clean room without special isolators. M. leprae-infected nude mice are being used as models fo r chemotherapeutic and immunologic studies. Other work has utilized neonatally thymectomized Lewis rats and congenitally athymic rats.
Renewed efforts to utilize primates as models of leprosy have been successful. Naturally occurring leprosy has been reported in a sooty mangabey monkey. The animal, captured in West Africa and subsequently suspected of having leprosy, was fu rther investigated and the diagnosis confirmed. Histologically the lesions were of the sub-polar lepromatous type of leprosy. The AFB fo und in large numbers were indistinguishable fr om M. leprae by the available parameters of identification. The organisms fr om this monkey were passaged to 2 mangabey monkeys, 2 rhesus monkeys, 3 African green monkeys and 3 squirrel monkeys. Inoculation was by intravenous as also intracutaneous routes except in one rhesus monkey which received only intracutaneous inoculation. The dose inoculated was of the order of 109• The mangabey, the rhesus and the African green monkeys developed leprosy within 2 years. The rhesus monkey inoculated intracu taneously and the squirrel monkeys did not develop the disease. Human (armadillo adapted) M. leprae were inoculated to mangabey, rhesus and African green monkeys. The mangabey monkey showed evidence of dissemination of disease in 10 months. No manifestations of the disease were evident in the rhesus and African green monkeys at 28 months.
K V DESIKAN, Chairman R C HASTINGS, Rapporteur
Microbiology ANIMAL SOU RCES OF BA CTERIA Colonies of infected nine-banded armadillos are established in several countries. The nu/nu mouse is a promising alternative.
PURIFICATION
The IMMLEP 1/79 process yields .antigenically intact bacteria with some adsorbed host material (removable by fu rther processing). Methods using density gradients, including unit gravity sedimentation, have been described; the products have been less well characterized.
STRUCTURE AND ULTRASTRUCTURE
The capsular material around My cobacterium leprae is ultrastructurally and chemically distinct fr om that around organisms of the MAIS group. The plasma membrane differs fr om that of other mycobacteria, since the leaflets seem symmetrical. Polysaccharide-specific stains give a characteristic appearance.
CHEMICAL STRUCTURE
Four types of characteristically myco b acterial lipid occur in M. leprae: mycolic acids, phthiocerol dimycocerosate, phenolic glycolipid and tuberculosteric acid. The glycolipid is serologically active and apparently antigenically unique; it is a major capsular component.
MOLECU LAR BIOLOGY
DNA has been isolated fr om M. leprae. The genome size is in the mycobacterial range, but its G + C ratio is significantly low. Hybridization confirms that the organisms from experimental and 'natural' armadillo infection belong to the same species. Homology with other mycobacterial species is reported to be in the range of from 7 to 26%; homology with some corynebacteria is from 20 to 28%.
Although the whole genome is thought to have been cloned in E. coli, no expression has been detected.
The organisms will bind some types of mycobacteriophage but there is no evidence for multiplication.
ANTIGENICITY
My cobacterium leprae possesses specific antigens and common mycobacterial antigens perhaps including one of ribosomal origin. Cell clones recognize antigenic determinants of mycobacteria that do not conform to conventional taxonomy. At least two different immune-suppressor activities have been recognized in other mycobacteria and these may be present in M. leprae.
BIOCHEMISTRY
Uptake of DOPA or incorporation of thymidine by suspension, or incorporation of thymidine in macrophage culture, has been used to screen drug sensitivity (and also viability). Measurement of A TP content is a sensitive measure of the metabolic state of organisms.
Uptake of glucose, amino acids and other potential nutrients occurs.
Glycolysis, the pentose-phosphate pathway and the tricarboxylic acid cycle appear to operate in M. leprae. Nucleic acid synthesis uses 'salvage' pathways, as in some protozoan parasites. Many individual enzyme activities have been detected and dis tinguished from host-derived activity. Superoxide dismutase is present but catalase has not been detected.
CUL TIV A TION
Three types of organisms have been cultivated from infected tissues: i, mycobacteria; ii, corynebacteria resembling human pathogenic corynebacteria; iii, morphologically variable organisms with some acid-fast fo rms.
Type i has been reported to change its properties, especially effects on cells, during subculture. Traces of serologically active glycolipid have been detected. Type ii has been well characterized in biochemical terms. An improved culture system has been described fo r type iii. None of these much resembles M. leprae isolated from tissues.
PROSPECTS
The leprosy bacillus grown in vivo emerges as a mycobacterium-like organism with several curious fe atures. Its metabolic processes are understood in outline and several measures of viability are, or are being, developed. The prospects for cultivation of organisms having identical properties seem good.
P DRAPER, Chairman S R PATTYN, Rapporteur
Workshop report on immunology of leprosy Major advances made in the past 5 years in the understanding of immune responses in leprosy were discussed. Though universal agreement on mechanisms underlying the unresponsiveness in lepromatous leprosy was lacking, interesting in vitro studies indicated that several suppressive mechanisms were operative. One study showed that My cobacterium leprae and phenolic glycolipid induced OK T8( + ) T cells capable of suppressing mitogen responsiveness were present in lepromatous individuals. Their activity was reversed by chemotherapy and immunotherapy with BCG + killed M. leprae. Other studies reported diverse membrane-associated alterations in blood-borne macrophages of lepromatous patients and 75% familial contacts. These changes were specific for M. leprae in the patient group. Fc, HLA-DR and Con A receptors were fo und to be diminished and macrophage lysates inhibited lymphocyte responses. Moreover, LL monocytes inhibited antigen-induced lymphoprolife ration through the release of soluble factor(s). The inhibitory factors were heat stable, indomethacin resistant and were greater than 25,000 molecular weight. Macrophage lysates, monocytes and monocyte-released soluble factors fr om LL patients inhibited antigen-induced lymphoproliferation. Production of gamma interferon, a macro phage activating factor was fo und to be reduced in lepromatous patients. However, LL monocytes were capable of responding to it in microbiocidal assays. Interleukin 1 (lymphocyte activating factor) production in response to M. leprae was fo und to be normal but interleukin 2 (T cell growth factor) was not detectable in lepromatous leprosy. Interestingly, antigen responsive lymphocytes were also observed in some lepromatous patients. Addition of exogenous IL 2 along with M. leprae restored proliferative responses and reversed the gamma interferon defect. Similar data was obtained in C57 BL mice infected intra venously and subcutaneously with M. lepraemurium. Moreover, murine T cell clones induced by M. leprae were shown to produce IL 2, macrophage activating factor, gamma interferon and proliferative responses and to induce delayed hypersensitivity reaction, bactericidal and tumourcidal activity. The T cell clone technology in analysing immune mechanisms in leprosy was further emphasized. Alteration ofT cell subsets as well as the characterization of immune complexes in erythema nodosum leprosum and reversal reactions were reported. Moreover, M. leprae antigens were recognized in the immune complexes and a possible defect in their handling in reactional patients was postulated.
An important advance has been the detection and characterization of M. leprae antigens in several laboratories. A unique phenolic glycolipid present in M. leprae and not in other related mycobacteria has been characterized and partly synthesized. Leprosy patients have been shown to have mainly IgM and IgG antibodies to this antigen. Chemotherapy reduced antibody titres but immuno therapy with BCG + heat killed M. leprae had no effect. Healthy individuals and tuberculosis patients did not show antibodies to the phenolic glycolipid. In addition, protein and glycoprotein of 12 KD antigens specific for M. leprae were described. A skin test antigen which measures 24 h delayed hypersensitivity is also being characterized. Specific monoclonal antibodies against the glycolipid and protein antigens have been developed. Possible tests for the early diagnosis of leprosy and for immuno-epidemiological studies were discussed. ELISA, radioimmunoassay and indirect immunofluorescence against several M. leprae antigens are being tested in the field. Concomitant skin tests and tests fo r presence of antibodies may help in the identification of high risk groups in the community. Such tests would be of value in not only ,understanding the disease, but in screening for fu ture vaccine trials.
The fe asibility of developing immunoprophylaxis and immunotherapy for leprosy was indicated in three studies. M. 'leprae BCG, JCRC and M. Wand acetoacetylated M. leprae are being investigated in Venezuela and India. Some 50-70% lepromatous patients showed conversion from negative lepromin reactivity to positivity status, and developed reversal reactions. Skin biopsies revealed upgrading of tissue reaction and bacillary clearance of significance was the conversion of 90% of lepromin-negative healthy individuals to lepromin positivity with all of the above preparations.
In order to generate alternative sources of production of M. leprae antigens libraries of M. leprae DNA cloned in E. coli have been made in the USA and India. Recent studies on the relationship of M. leprae Schwann cells and axons in nerve damage associated with leprosy were presented. One study also showed a deficiency of zinc and alterations in Langerhans' cells in LL patients. An association between HLA DR2 and tuberculoid leprosy has been confirmed. Furthermore HLA MTI has been shown to be associated with lepromatous leprosy in one study. A general improvement of cellular immunity and immunoregulatory T cell fu nction by a synthetic thymic factor was reported in experimental models and human disease.
The understanding of inverse relationship between genetically controlled natural resistance to primary attack by live mycobacteria and the ensuing disease and cell-mediated immunity in mice were discussed. Preliminary data fo und in human leprosy seems to indicate analogous mechanisms. Several of the above studies suggest that lepromatous population is heterogenous in its restoration of responsiveness in vitro as well as after specific immunotherapy. Such differences in the population as well as genetic and environmental fa ctors need to be precisely defined for fu ture strategy fo r the control of the disease. During the past 5 years, awareness has been heightened of the threat to leprosy control posed by drug resistance, especially resistance to dapsone. Secondary resistance to dapsone has been recognized wherever it has been sought. Moreover, organisms with a low degree of resistance to dapsone have been encountered in as many as 50% of patients with previously untreated lepromatous leprosy. Although these patients should nevertheless respond to treatment with dapsone in full dosage, this observation suggests an alarming situation.
The increasing prevalence of dapsone-resistant strains of My cobacterium leprae requires that all multibacillary patients be treated with a combination of drugs. In addition to rifampicin, clofazimine and ethionamide or prothionamide, other well-tolerated bactericidal drugs are urgently needed. One of the major requirements for the development of new drugs is appropriate, in vitro methods fo r screening large numbers of compounds for activity against M. leprae. A number of methods are currently being evaluated. For example, 'M.lu fu' is being used in the search for inhibitors of the dihydrofolate reductase of M. leprae. In addition, advances in our knowledge of the biochemistry of M. leprae may provide leads to other target enzymes.
The ubiquity of poor drug compliance emphasizes the importance of using drugs that are effective when administered intermittently under supervision.
Persistent M. leprae-i.e. drug-susceptible organisms that survive prolonged treatment by adequate chemotherapy-have been detected in significant propor tions of patients treated by a variety of multidrug regimens, among them regimens consisting of rifampicin, dapsone and c10fazimine or prothionamide, each drug administered continuously in fu ll dosage for 2 years. This suggests that no multidrug regimen is likely to eliminate persisting M. leprae. On the other hand, it is not certain that cure of multibacillary leprosy requires that all of the persisting organisms be killed. An 8-year fo llow-up of more than 300 multibacil lary patients released from control after 20 years of well-supervised monotherapy with dapsone in fu ll dosage yielded a relapse rate of only I % per year. Among more than 100 multibacillary patients who had been treated with 2 years of intensive multidrug therapy after dapsone monotherapy of variable duration, no relapses were noted during a fo llow-up of 8-9 years. Thus, the use in leprosy control of intensive multidrug treatment of limited duration appears justified. Mathematical modelling may permit a more detailed understanding of the dynamics of the multi bacillary patient's bacterial popUlation during chemo therapy.
L LEVY, Chairman ELEANOR STORRS, Rapporteur
Workshop on epidemiology and leprosy control Significant progress has been achieved in our understanding of the epidemiology of leprosy since the last International Leprosy Congress. This has resulted in striking changes in the classical strategy fo r leprosy control which was previously based on dapsone monotherapy. ii Transmission. The importance of airborne spread as one of the methods of transmission of M. leprae has gained wide acceptance. The viability of M. leprae outside the human host fo r at least 10 days has now been firmly established. The role of paucibacillary cases in the transmission of M. leprae has not yet been clarified. Similarly, the importance of finding AFB in the nasal mucosa and skin of individuals with no clinical disease, poses the question of the carrier state in leprosy and requires elucidation.
Mycobacteria indistinguishable fr om M. leprae have been identified in the environment. Isolation of similar organisms from animals, with or without a leprosy-like disease, raises the question of host specificity of M. leprae to man.
III
Im muno-epidemiology . Significant advances have been achieved in the development of immunological tools fo r the recognition of M. leprae infection. The FLA-ABS test, the ELISA technique using phenolic glycolipid antigens and inhibition assays based on monoclonal antibodies deserve special mention. Recent studies with currently available tests provide strong presumptive evidence that the incidence and prevalence of M. leprae infection far exceeds clinical leprosy in endemic areas. Availability of a sensitive and specific test fe asible under field conditions to identify M. leprae infection, is an urgent requirement fo r the proper understanding of the epidemiology of leprosy and the effects of control measures.
iv Genetic fa ctors. Data on fa mily segregation analyses of HLA, provide evidence of some genetic involvement in tuberculoid and perhaps also leproma tous disease response. Further studies are required in this direction.
v Drug resistance. Secondary dapsone resistance has been reported from more than 25 countries and its prevalence is steadily increasing. Primary dapsone resistance is also being reported with increasing frequency fr om several countries. Similarly, there have been reports of M. leprae showing resistance to rifampicin and to other drugs.
In dicators of declining trends
Indicators of declining trends have now been identified by studies from Norway, Japan, the Philippines and Venezuela, based on the fact that the decline in incidence rates has been paralleled by a change in the distribution of age at onset towards older age groups. The usefulness of such indicators needs to be fu rther evaluated.
LEPROSY CONTROL
i Multidrug therapy. Two threats to the successful implementation of the classical strategy for leprosy control are the widespread emergence of dapsone resistant strains of M. leprae and the problem of persistence of bacilli. The best way to prevent the spread of dapsone-resistant leprosy is to use multidrug therapy. Only 4 drugs can be recommended for combined therapy, namely rifampicin, clofazimine, dapsone and prothionamide/ethionamide. In 1981 the WHO Study Group on the Chemotherapy of Leprosy fo r Control Programmes recommended combined therapeutic regimens fo r the treatment of both multi bacillary and paucibacillary leprosy.
While this workshop endorses the principles underlying the use of multidrug therapy in leprosy, based on the WHO recommendations, it also recognizes the fact that the schedules adopted by different countries vary in detail. All regimens need to be evaluated with special emphasis on relapse rates, occurrence of reversal reactions, side-effects of drugs and operational fe asibility. Reactions should be clearly distinguished fr om relapses in such evaluations. The workshop recom mends the development of a simple serological test to monitor the success of treatment.
ii Strengthening of the in frastructure. It is now essential to perform bacteriologi cal examinations and to classify patients correctly, since drug regimens are different for multibacillary and paucibacillary leprosy patients. The critical fa ctor will be the flexibility of the treatment delivery system which should be tailored to meet the individual needs of patients. Continuity, regularity and completion of chemotherapy will be the keys to the success of the new strategy. The logistics of drug availability and their supply to the periphery and the retraining of staff to cope with their increased responsibilities need to be adequately strengthened. Regularity of treatment, completion of treatment and duration of surveillance should be defined in the context of implementation of multi drug therapy. Patients should be considered to have completed treatment, if they have taken 6 supervised monthly doses, within a period of 9 months in paucibacillary leprosy, and 24 supervised monthly doses, within a period of 36 months in multibacillary leprosy. It is also recommended that surveillance should be continued fo r at least 2 years for paucibacillary patients and for 5 years for multibacillary patients, after completion of the course of treatment.
A patient who has been absent for I calendar year may be considered to be 'out of control'. iii In formation system. A suitable recording, reporting and information support system, based on the OMSLEP pattern, should be designed and used. The information requirements at various levels of the health care delivery system must be explained to the personnel so that the reasons for the collection of data become meaningful to them. Completeness of case ascertainment should be an area of priority, and special attention must be given to the problems of under-reporting and multiple registration. Simple and robust indicators fo r epidemiological surveillance and operational monitoring of control programmes should be developed and applied. It is recommended that whenever statistics are quoted, they should include a precise description of their derivation. It is fu rther recommended that patients on treatment be considered separately fr om those under surveillance.
iv Primary health care approach. In endemic areas, with integrated health services, the fu ll resources of the primary health care delivery system must be mobilized to implement and support the programme, so that its optimal potential can be put to maximum utilization. Every effort must be made to promote community involvement. The key factor in the primary health care approach is its fo cus on the consumers of the health care system. Practical methods to promote awareness and generate community involvement need to be identified, through field oriented studies.
v Urban leprosy control. In the endemic countries, increasing urbanization has resulted in the emergence of leprosy as a major public health problem in towns and cities. Prospective planning should therefore emphasize the fo rmulation of urban leprosy control programmes so as to meet the challenges that lie ahead.
vi Primary prevention. Non-availability of an effective and practical method of specific protection has been a major impediment in the control of leprosy. Although moderate efficacy of chemoprophylaxis with dapsone and acedapsone has been established under trial conditions, mass chemoprophylaxis is not operationally feasible in a service programme. However, in this context, chemoprophylaxis with a single dose of rifampicin needs to be investigated.
An armadillo-derived killed M. leprae vaccine has been shown to confer protective immunity in animal models. Its evaluation in humans is now being undertaken through small-scale studies. Vaccines derived fr om related mycobac teria are also being developed. It will, however, be several years before accurate information regarding the efficacy of these vaccines can be established. Prior to the workshop, it was agreed to fo cus on the selection, production and distribution of books and pamphlets for leprosy control workers. There were 4 reasons for this:
Appropriate literature is still by far the most influential source of new information and ideas. 2 Books do not require any elaborate apparatus for their effective use.
3 Books are relatively cheap to produce and distribute. 4 Really good and appropriate written learning material can make a great contribution to the effective training of the large numbers of health workers who will become responsible fo r leprosy patient care in integrated and primary health care programmes.
However, the participants of the workshop were also aware that much of the reading material available is not entirely appropriate and that distribution of appropriate literature is very patchy.
AIMS
The aims of the workshop were as fo llows:
To prepare a short list of current titles in English appropriate fo r various categories of health staff. 2 To identify gaps in existing literature in English.
3 To prepare similar lists of material available in languages other than English, especially in major international 1anguages. 4 To outline proposals for fu rther development of effort to produce, distribute and assess material fo r leprosy workers.
PROCEEDINGS

Based on previous work done primarily by INFOLEP in Amsterdam and The
Leprosy Mission (International) in London and the varied experience of the workshop participants, short lists of books in English appropriate for 6 broad categories of workers were prepared and a number of important gaps and deficiencies in the literature were identified. Due to limited time and lack of fu ll representation, it was decided not to attempt to do the same fo r other languages at this time.
The second day of the workshop was taken up with the presentation (by participants) of field experience in production, distribution and utilization of learning materials in a variety of situations at the central and peripheral levels. This was fo llowed by a sharing of AMREF experience in East Africa in line production and distribution of learning materials in the field of general health by Dr Christopher Wood. Extensive and frank discussion intensified the exchange of information and ideas.
CONCLUSIONS
A great variety of literature exists in English and with a few exceptions can potentially meet the need of most workers who can read that language with reasonable fluency. There are, however, 3 areas where improvement is essential:
Much of the existing literature could be made more useful by simplifying the language and improving presentation. 2 Distribution leaves much to be desired: many workers are not even aware of the existence of literature which could help them and the present system for distribution of material often fails to deliver literature to those who need it.
3 Many students and workers have little or no skill in the use of literature as an aid to learning for basic or continuing fo rmal or non-formal education.
It is apparent that there is a serious shortage of readily available material in languages other than English, especially for paramedical workers. Translation of existing English material is one way of coping with this situation. But translation of technical material is not easy, and translations, even by experts in linguistics, should be checked fo r technical accuracy by people fa miliar with both the language and the subject matter.
RECOMMEND A TIONS
The contribution of appropriate learning material to the competency and motivation of workers should be recognized and fu nds for literature should be provided as an essential item in every leprosy control programme. 2 Efforts to collect and disseminate information about literature in languages other than English should continue. 3 Assessment and subsequent improvement of existing material in English should in general have priority over production of new material in that language. 4 Efforts to provide learning material for field workers in local languages should be intensified since there is a notable lack of literature for this particular group. S Training in the use of written material should be an integral part of basic and refresher courses for all staff. 6 Effective distribution of literature, especially to staff at the periphery, is as important as the distribution of drugs and should be given similar priority.
W F ROSS, Chairman A C McDOUGALL, Rapporteur
Social aspects
POLICY ST A TEMENT
The aim of social research in leprosy should be to assist in improving the policy and execution of leprosy control. At the same time, it should contribute to a conceptual framework which helps to understand the social, economic and psychological problems experienced by leprosy patients, their relatives and health staff concerned. These topics have been elaborated in a number of meetings organized by WHO and national/international leprosy associations.
PROPOSALS
This working group strongly encouraged a comprehensive approach to problems in leprosy control, paying equal attention to fa ctors related to the patient, his near surroundings and to the leprosy services. Research should ultimately concentrate on those areas where problems are most obvious and where remedial action seems most fe asible.
The fo llowing topics were proposed fo r elaboration:
(a) Definition by community and patients of the concepts of illness and cure in leprosy: Terminology of different manifestations/stages of leprosy used by community and patients.
(b) Stigma: Possible differences between perception of stigma by community members and patients, and the degree of stigma actually experienced. Forces that make some leprosy patients stigmatize themselves (comparative research). Mechanisms that help patients to maintain and regain their social and economic position in society; determinants of self-acceptance and community acceptance of patients.
(c) Evaluative research of: Acceptability to patients, community and health staff of different types and ways of providing services. Content and impact of health education. The possible contribution of community, leprosy patients and social services to leprosy control, including care of the handicapped. Economic and social consequences of reconstructive surgery.
(d) Participation in the planning and monitoring of trials with multi drug therapy; evaluation of the effect of MDT on community and patient perceptions of leprosy.
(e) Participation in planning, monitoring and evaluation of vaccine trials in the field.
(f) Investigation of factors in human behaviour which may be contributing to transmission of leprosy, e.g. migration.
RESEARCH METHODS
A combination of research methods should be used: study of relevant documents; informal and fo rmal interviews; questionnaires; systematic observations. Questionnaires as a single research tool may give superficial and misleading results.
IMPLEMENT A nON OF RESEARCH RESUL TS
Social research should provide direction fo r possible solutions to problems, as well as alternative proposals for action.
The results should be presented in terms which are understandable to the potential users. Implementation of research results will be more effective if the social scientists who conducted the research are invited to participate.
In order to increase the quality and quantity of social research and its impact on leprosy control, it was suggested that regional centres be developed as fo cal points fo r collection and dissemination of research results. These centres would also develop training programmes for social research in leprosy and carry out investigations.
The manual on Social Dimensions of Leprosy (published by ILEP, 1982) was discussed in the workshop. This book could be useful to paramedical teachers who have some training in social sciences and who can adapt it for local use.
In order to be useful at the field level, the theoretical part needs considerable revision and fo cussing on the working situation of field staff. CORLIEN M V ARKEVISSER, Chairperson F GIRARDIN, JUDITH JUSTICE and PATRICIA ROSENFIELD, Rapporteurs
